Evidence map›Paper›PMID 28790337›Full record

ArticleScientific reports2017

From Mechanistic Study to Chiral Catalyst Optimization: Theoretical Insight into Binaphthophosphepine-catalyzed Asymmetric Intramolecular [3 + 2] Cycloaddition.

Meng Duan, Lei Zhu, Xiaotian Qi, Zhaoyuan Yu, Yingzi Li, Ruopeng Bai, Yu Lan

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meng DuanSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China.
Lei ZhuSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China.
Xiaotian QiSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China.
Zhaoyuan YuSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China.ORCID 0000-0002-9570-3512
Yingzi LiSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China.
Ruopeng BaiSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China. ruopeng@cqu.edu.cn.ORCID 0000-0002-1097-8526
Yu LanSchool of Chemistry and Chemical Engineering, Chongqing University, Chongqing, 400030, China. lanyu@cqu.edu.cn.ORCID 0000-0002-2328-0020

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Density functional M11 was used to study the mechanism and enantioselectivity of a binaphthophosphepine-catalyzed intramolecular [3 + 2] cycloaddition reaction. The computational results revealed that this reaction proceeds through nucleophilic addition of the phosphine catalyst to the allene, which yields a zwitterionic phosphonium intermediate. The subsequent stepwise [3 + 2] annulation process, which starts with the intramolecular nucleophilic addition of the allenoate moiety to the electron-deficient olefin group, determines the enantioselectivity of the reaction. This step is followed by a ring-closing reaction and water-assisted proton-transfer process to afford the final product with concomitant regeneration of the phosphine catalyst. Theoretical predictions of the enantioselectivity for various phosphine catalysts were consistent with experimental observations, and 2D contour maps played an important role in explaining the origin of the enantioselectivity. Moreover, on the basis of our theoretical study, new binaphthophosphepine catalysts were designed and that are expecting to afford higher enantioselectivity in this cycloaddition reaction.

Identifiers

PMID28790337
PMCPMC5548760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.